Performance Forecasts - Yinglian Co., Ltd. expects a net profit growth of 1531.13% to 1672.97% year-on-year for the first three quarters [1] - Dalian Heavy Industry anticipates a net profit growth of 19.91% to 28.52% year-on-year for the first three quarters [1] Project Investments - Wharton Technology plans to invest in the enhancement of membrane materials and membrane components [1] - Jiufeng Energy intends to invest in a coal-to-natural gas project in Xinjiang [1] Contract Awards - Qiaoyin Co., Ltd. is pre-awarded a contract worth approximately 512 million yuan for integrated sanitation operations in Laishui County, Baoding City, Hebei Province [1] - Dash Smart signed a contract for a smart hospital project worth 113 million yuan [1] Equity Acquisitions - Conch New Materials plans to acquire 51% equity in North China Plastics [1] - Suochen Technology intends to acquire 60% equity in Likong Technology [1] - Jingye Intelligent plans to acquire 51% equity in Hefei Shengwen for 108 million yuan [1] - Landi Group plans to acquire 20.1667% equity in Jujia Technology for 121 million yuan [1] Share Buybacks - Hanshuo Technology plans to repurchase shares worth between 150 million yuan and 300 million yuan [2] - Youke De intends to spend between 8 million yuan and 10 million yuan on share buybacks [2] H-Shares - Jinghe Integrated Circuit has submitted an application for H-share issuance and listing on the Hong Kong Stock Exchange [2] - Lingyi Manufacturing is planning to issue H-shares and list on the Hong Kong Stock Exchange [2] - Changchun High-tech has submitted an application for the issuance of H-shares [2] Shareholding Changes - Senba Sensor's actual controller plans to reduce holdings by no more than 1.09% [3] - Erkang Pharmaceutical's controlling shareholder intends to reduce holdings by no more than 2.04% [3] - Andeli's BVI Donghua plans to reduce holdings by no more than 1.00% [3] - Zhiyang Innovation's controlling shareholder and its concerted actioner plan to reduce a total of no more than 4.225 million shares [3] - Xizi Clean Energy's chairman plans to increase holdings by 30 million to 50 million yuan [3] Other Activities - Luoxin Pharmaceutical plans to raise no more than 842 million yuan for innovative drug research and development projects [3] - Huaxin Xinchang has received project designation notification from Jiangqi Group [3] - Jinpu Garden plans to raise no more than 129 million yuan through a private placement to Nanjing Lisen [3]

Group 1 - The company has proposed amendments to its Articles of Association and related rules, which will be submitted for approval at the shareholders' meeting [1][2] - The company plans to abolish the supervisory board and its positions, transferring the legal responsibilities of the supervisory board to the audit committee of the board of directors [1] - The current supervisory board will continue to fulfill its supervisory duties until the shareholders' meeting approves the amendments, after which the supervisory board will cease to function [2] Group 2 - The company expresses gratitude to the current supervisors for their contributions to corporate governance and development during their tenure [2] - The supervisors do not hold any direct shares in the company, but two of them hold indirect shares through the company's employee stock ownership plan [2] - The amendments to the Articles of Association are in accordance with the Company Law and relevant regulations, reflecting the company's actual situation [1]

Core Viewpoint - The company, 罗欣药业, has announced a plan to issue A-shares to specific investors, aiming to raise up to 842.4 million RMB for various projects [1] Group 1: Fundraising Details - The issuance will target no more than 35 specific investors, including legal entities, individuals, or other legitimate investment organizations [1] - The total amount to be raised is capped at 842.4 million RMB, which includes the principal amount [1] Group 2: Use of Proceeds - The funds raised will be allocated to several key projects: - Innovative drug research and development projects - Expansion and technical upgrades of raw material drug production facilities - Supplementing working capital [1]

Core Viewpoint - 罗欣药业 plans to issue A-shares to specific investors, aiming to raise up to RMB 842.4 million for various projects [1] Group 1: Fundraising Details - The company intends to issue shares to no more than 35 qualified investors, including legal entities, individuals, or other legitimate investment organizations [1] - The total amount of funds to be raised is capped at RMB 842.4 million, which includes the principal amount [1] Group 2: Use of Proceeds - The raised funds will be allocated to the following projects: innovative drug research and development, expansion and technical upgrades of raw material drug production, and supplementing working capital [1]

Group 1 - The company, Luoxin Pharmaceutical (002793.SZ), plans to raise a total of no more than RMB 842.40 million through a private placement of shares [1] - The funds raised will be allocated to innovative drug research and development projects, expansion and renovation of raw material drug production facilities, and upgrading of freeze-drying workshops, as well as to supplement working capital [1]

Group 1 - The core point of the article is that Luoxin Pharmaceutical (002793) plans to issue A-shares to specific investors, aiming to raise no more than 842 million yuan, which will be used for various projects including innovative drug research and development, raw material drug expansion and transformation, and to supplement working capital [1] Group 2 - The total amount to be raised from the issuance is capped at 842 million yuan, including the principal amount [1] - The funds will be allocated to three main areas: innovative drug R&D projects, the expansion and technical transformation of raw material drug production, and to enhance the company's liquidity [1]

证券代码：002793 股票简称：罗欣药业 公告编号：2025-088 罗欣药业集团股份有限公司 关于最近五年被证券监管部门和交易所 采取监管措施或处罚情况的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 罗欣药业集团股份有限公司（以下简称"公司"）一直严格按照《中华人民 共和国公司法》《中华人民共和国证券法》《深圳证券交易所股票上市规则》《深 圳证券交易所上市公司自律监管指引第 1 号——主板上市公司规范运作》等法律 法规、规范性文件及《罗欣药业集团股份有限公司章程》的相关规定和要求规范 运作。鉴于公司本次拟向特定对象发行股票，根据相关要求，公司对最近五年被 证券监管部门和证券交易所采取监管措施或处罚的情况进行了自查，结果如下： 一、公司最近五年被证券监管部门和证券交易所处罚的情况 公司最近五年不存在被证券监管部门和交易所处罚的情况。 二、公司最近五年被证券监管部门和证券交易所采取监管措施的情况 | 监管对象名称 | 监管文件名称 | 监管措施 | 公告披 | 公告名称 | | --- | --- | --- | --- | --- | | | 及文号 ...

证券代码：002793 股票简称：罗欣药业 公告编号：2025-085 罗欣药业集团股份有限公司 第五届监事会第二十五次会议决议公告 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、监事会会议召开情况 2025 年 9 月 29 日，罗欣药业集团股份有限公司（以下简称"公司"）第五 届监事会第二十五次会议在山东省临沂高新技术产业开发区罗七路管理中心三 楼会议室以现场表决和通讯表决相结合的方式召开。会议通知已于 2025 年 9 月 26 日以电话、专人送达、电子邮件等方式发出。本次会议应出席监事 3 名，实 际出席监事 3 名。监事会主席宋良伟女士主持了本次会议。本次监事会按照《中 华人民共和国公司法》（以下简称"《公司法》"）及其他法律法规和《罗欣药业集 团股份有限公司章程》（以下简称"《公司章程》"）的规定召开，会议程序合法有 效。 二、监事会会议审议情况 （一）审议通过《关于公司符合向特定对象发行 A 股股票条件的议案》 根据《公司法》《中华人民共和国证券法》（以下简称"《证券法》"）、《上市 公司证券发行注册管理办法》（以下简称"《注册管理办法》" ...

书面审核意见 罗欣药业集团股份有限公司（以下简称"公司"）监事会根据《中华人民共 和国公司法》（以下简称"《公司法》"）、《中华人民共和国证券法》（以下简称"《证 券法》"）、《上市公司证券发行注册管理办法》（以下简称"《注册管理办法》"）等 法律、法规和规范性文件的要求，在全面了解和审核公司 2025 年度向特定对象 发行 A 股股票的相关文件后，发表书面审核意见如下： 1．根据《公司法》《证券法》《注册管理办法》等法律法规和规范性文件的 规定和要求，我们认为公司符合现行法律法规和规范性文件规定的上市公司向特 定对象发行 A 股股票的资格和条件。 罗欣药业集团股份有限公司监事会 关于公司 2025 年度向特定对象发行 A 股股票相关事项的 2025 年 9 月 29 日 回报的意愿，符合中国证监会《上市公司监管指引第 3 号——上市公司现金分红 （2025 年修订）》和其他相关文件的精神以及《罗欣药业集团股份有限公司章程》 （以下简称"《公司章程》"）的规定，有利于保护股东特别是中小股东的利益。 6.公司拟在本次发行取得股东大会审议通过、深圳证券交易所审核通过及中 国证监会同意注册后，设立公司向特定对象发行 ...

罗欣药业集团股份有限公司 第五届董事会第三十次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 证券代码：002793 股票简称：罗欣药业 公告编号：2025-084 一、董事会会议召开情况 2025 年 9 月 29 日，罗欣药业集团股份有限公司（以下简称"公司"）第五 届董事会第三十次会议在山东省临沂高新技术产业开发区罗七路管理中心三楼 会议室和上海市浦东新区前滩世贸中心会议室以现场表决和通讯表决相结合的 方式召开。会议通知已于 2025 年 9 月 26 日以电话、专人送达、电子邮件等方式 发出。本次会议应出席董事 5 名，实际出席董事 5 名，公司监事、高级管理人员 列席了会议。公司董事长刘振腾先生主持了本次会议。会议的召集、召开符合《中 华人民共和国公司法》（以下简称"《公司法》"）等法律法规、规范性文件和 《罗欣药业集团股份有限公司章程》（以下简称"《公司章程》"）的规定，合 法有效。 二、董事会会议审议情况 （一）审议通过《关于修订<公司章程>的议案》 根据《公司法》《上市公司章程指引》等法律法规、规范性文件的规定，并 结合公司实际情 ...